{"component": "clause", "props": {"groups": [{"size": 4, "snippet_links": [{"key": "directorate-of-defense-trade-controls", "type": "clause", "offset": [39, 76]}, {"key": "provide-documentation", "type": "clause", "offset": [106, 127]}], "snippet": "Applicants: 6. Are you registered with Directorate of Defense Trade Controls (DDTC)? If yes, state so and provide documentation.", "samples": [{"hash": "cbhHkRbbQ0D", "uri": "/contracts/cbhHkRbbQ0D#for-us", "label": "Militarily Critical Technical Data Agreement", "score": 32.1690979004, "published": true}, {"hash": "jmPSltdl5Ls", "uri": "/contracts/jmPSltdl5Ls#for-us", "label": "Militarily Critical Technical Data Agreement", "score": 30.9504928589, "published": true}, {"hash": "aQHpYwgWIXc", "uri": "/contracts/aQHpYwgWIXc#for-us", "label": "Militarily Critical Technical Data Agreement", "score": 30.9504852295, "published": true}], "hash": "1c4454c73e5700f4c1dc606804566c2f", "id": 1}, {"size": 2, "snippet_links": [{"key": "government-entities", "type": "clause", "offset": [24, 43]}, {"key": "a-us", "type": "clause", "offset": [60, 65]}, {"key": "state-government-entity", "type": "definition", "offset": [83, 106]}, {"key": "the-agreement", "type": "clause", "offset": [113, 126]}, {"key": "governing-law-and-venue", "type": "definition", "offset": [152, 175]}], "snippet": "City, County, and State Government Entities. If Customer is a U.S. city, county or state government entity, then the Agreement will be silent regarding governing law and venue.", "samples": [{"hash": "5mUPs6KhdAF", "uri": "/contracts/5mUPs6KhdAF#for-us", "label": "Google Maps Platform License Agreement", "score": 35.4505653381, "published": true}, {"hash": "cNPuO3COCtQ", "uri": "/contracts/cNPuO3COCtQ#for-us", "label": "Google Terms of Service for Apigee Products", "score": 26.3210124969, "published": true}], "hash": "7e2499c376a5af78a0f7ff970cd9ead7", "id": 2}, {"size": 2, "snippet_links": [{"key": "significant-costs", "type": "definition", "offset": [119, 136]}, {"key": "development-and-commercialization", "type": "clause", "offset": [239, 272]}, {"key": "reliance-on-third-parties", "type": "clause", "offset": [329, 354]}, {"key": "trade-secrets", "type": "clause", "offset": [383, 396]}, {"key": "agreements-with-third-parties", "type": "clause", "offset": [556, 585]}, {"key": "with-respect-to", "type": "clause", "offset": [586, 601]}, {"key": "drug-products", "type": "definition", "offset": [618, 631]}, {"key": "development-of", "type": "clause", "offset": [666, 680]}, {"key": "to-develop", "type": "definition", "offset": [949, 959]}, {"key": "market-potential", "type": "clause", "offset": [985, 1001]}, {"key": "ability-to", "type": "definition", "offset": [1049, 1059]}, {"key": "key-executives", "type": "clause", "offset": [1071, 1085]}, {"key": "qualified-personnel", "type": "definition", "offset": [1122, 1141]}, {"key": "our-operations", "type": "clause", "offset": [1310, 1324]}, {"key": "future-revenue", "type": "clause", "offset": [1404, 1418]}, {"key": "costs-and-expenses", "type": "definition", "offset": [1460, 1478]}, {"key": "computer-systems", "type": "definition", "offset": [1493, 1509]}, {"key": "other-contractors", "type": "definition", "offset": [1534, 1551]}, {"key": "security-breaches", "type": "clause", "offset": [1587, 1604]}, {"key": "material-disruption", "type": "definition", "offset": [1630, 1649]}, {"key": "drug-development-program", "type": "definition", "offset": [1657, 1681]}, {"key": "information-concerning", "type": "clause", "offset": [1706, 1728]}, {"key": "our-products", "type": "clause", "offset": [1729, 1741]}, {"key": "service-providers", "type": "definition", "offset": [1776, 1793]}, {"key": "ongoing-business", "type": "clause", "offset": [1798, 1814]}, {"key": "subject-to", "type": "clause", "offset": [1844, 1854]}, {"key": "business-and-operations", "type": "clause", "offset": [1908, 1931]}, {"key": "in-the-event-of", "type": "clause", "offset": [1945, 1960]}, {"key": "system-failures", "type": "clause", "offset": [1961, 1976]}, {"key": "information-technology", "type": "definition", "offset": [2003, 2025]}, {"key": "cybersecurity-incidents", "type": "clause", "offset": [2120, 2143]}, {"key": "to-operate", "type": "definition", "offset": [2168, 2178]}, {"key": "our-technology", "type": "definition", "offset": [2247, 2261]}, {"key": "drug-candidate", "type": "definition", "offset": [2266, 2280]}, {"key": "adversely-affected", "type": "definition", "offset": [2299, 2317]}, {"key": "ip-rights", "type": "clause", "offset": [2406, 2415]}, {"key": "the-world", "type": "definition", "offset": [2427, 2436]}, {"key": "patent-protection", "type": "clause", "offset": [2468, 2485]}, {"key": "compliance-with", "type": "definition", "offset": [2499, 2514]}, {"key": "document-submission", "type": "clause", "offset": [2535, 2554]}, {"key": "fee-payment", "type": "clause", "offset": [2556, 2567]}, {"key": "other-requirements", "type": "definition", "offset": [2572, 2590]}, {"key": "other-proceedings", "type": "clause", "offset": [2766, 2783]}, {"key": "other-ip", "type": "clause", "offset": [2821, 2829]}, {"key": "rights-of-third-parties", "type": "definition", "offset": [3014, 3037]}, {"key": "necessary-rights", "type": "clause", "offset": [3092, 3108]}, {"key": "competitive-position", "type": "definition", "offset": [3253, 3273]}, {"key": "our-employees", "type": "clause", "offset": [3308, 3321]}, {"key": "outside-contractors", "type": "clause", "offset": [3326, 3345]}, {"key": "former-employers", "type": "clause", "offset": [3394, 3410]}, {"key": "litigation-or-proceedings", "type": "clause", "offset": [3427, 3452]}, {"key": "our-personnel", "type": "clause", "offset": [3512, 3525]}, {"key": "the-\u2587", "type": "clause", "offset": [3599, 3604]}, {"key": "term-of", "type": "clause", "offset": [3678, 3685]}, {"key": "trademarks-and-trade-names", "type": "clause", "offset": [3798, 3824]}, {"key": "reform-measures", "type": "clause", "offset": [3988, 4003]}, {"key": "comply-with", "type": "definition", "offset": [4113, 4124]}, {"key": "healthcare-regulations", "type": "clause", "offset": [4125, 4147]}, {"key": "operations-and-financial-condition", "type": "clause", "offset": [4203, 4237]}, {"key": "health-and-safety-laws-and-regulations", "type": "clause", "offset": [4326, 4364]}, {"key": "exposed-to", "type": "definition", "offset": [4380, 4390]}, {"key": "in-connection-with", "type": "clause", "offset": [4426, 4444]}, {"key": "environmental-compliance", "type": "definition", "offset": [4445, 4469]}, {"key": "remediation-activities", "type": "definition", "offset": [4473, 4495]}, {"key": "business-and-financial-condition", "type": "clause", "offset": [4528, 4560]}, {"key": "employees-may", "type": "clause", "offset": [4566, 4579]}, {"key": "improper-activities", "type": "clause", "offset": [4610, 4629]}, {"key": "regulatory-standards", "type": "clause", "offset": [4660, 4680]}, {"key": "litigation-and-regulatory", "type": "clause", "offset": [4728, 4753]}, {"key": "generic-versions", "type": "definition", "offset": [4783, 4799]}, {"key": "if-approved", "type": "clause", "offset": [4899, 4910]}, {"key": "treatment-of", "type": "clause", "offset": [4943, 4955]}, {"key": "additional-regulatory-approvals", "type": "clause", "offset": [5075, 5106]}, {"key": "the-sale", "type": "clause", "offset": [5363, 5371]}, {"key": "liability-claims", "type": "clause", "offset": [5451, 5467]}], "snippet": "If one of our suppliers or manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts to find new suppliers or manufacturers. We may also face delays in the development and commercialization of SM-88 and any other drug product we may develop. Our reliance on third parties may require us to share our trade secrets, which increase the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. We may enter into license agreements with third parties with respect to SM-88 any other drug products we may develop that may place the development of SM-88 and any other drug products partially or entirely outside of our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us and, if our collaborations are not successful, SM-88 and any other drug products we may choose to develop may not reach their full market potential. Our future operational success depends on our ability to retain our key executives and to attract, retain and motivate qualified personnel. We expect to expand our development, regulatory and marketing capabilities and, as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. Business disruptions (domestic and/or international) could seriously harm our future revenue and financial condition and increase our costs and expenses. Our internal computer systems or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our drug development program. Substantial amounts of information concerning our products, employees, consultants, vendors, service providers and ongoing business are stored digitally and are subject to threats of theft, tampering, or other intrusion. Our business and operations would suffer in the event of system failures. We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively. Our ability to successfully commercialize our technology and drug candidate may be materially adversely affected if we are unable to obtain and maintain effective IP. We may not be able to protect our IP rights throughout the world. Obtaining and maintaining our patent protection depends upon compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies. Our patent protection could be reduced or eliminated for noncompliance with these requirements. We may become involved in lawsuits or other proceedings to protect or enforce our patents or other IP, which could be expensive, time-consuming and unsuccessful. Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. We may not be successful in obtaining or maintaining necessary rights to IP through acquisitions and in-licenses. We may be unable to protect the confidentiality of our trade secrets, thus harming our business and competitive position. We may be subject to claims that our employees and outside contractors have wrongfully used or disclosed IP from their former employers and clients. IP litigation or proceedings could cause us to spend substantial resources and distract our personnel from their normal responsibilities. If we do not obtain protection under the \u2587\u2587\u2587\u2587\u2587-\u2587\u2587\u2587\u2587\u2587\u2587 Amendments and similar non-U.S. legislation for extending the term of patents covering SM-88 and any other drug product we may develop, our business may be materially harmed. If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected. Health care reform measures could hinder or prevent the commercial success of SM-88 any other drug product we may develop. If we fail to comply with healthcare regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected. Because we and our suppliers are subject to environmental, health and safety laws and regulations, we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities, which may adversely affect our business and financial condition. Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. If generic manufacturers use litigation and regulatory means to obtain approval for generic versions of products on which our future revenue depends, our business will suffer. The marketing of SM-88, if approved, will be limited to use for the treatment of specific cancer indications and, if we want to expand the indications for which these drug candidates may be marketed, additional regulatory approvals will need to be obtained, which may not be granted. If SM-88 is approved for marketing and we are found to have improperly promoted off-label uses or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, significant fines, penalties, sanctions and drug liability claims. Additionally, our image and reputation within the industry and marketplace could be harmed.", "samples": [{"hash": "8AzGtQ8CtQk", "uri": "/contracts/8AzGtQ8CtQk#for-us", "label": "Securities Purchase Agreement (Tyme Technologies, Inc.)", "score": 27.1026687622, "published": true}, {"hash": "7967W1hUqLP", "uri": "/contracts/7967W1hUqLP#for-us", "label": "Securities Purchase Agreement (Tyme Technologies, Inc.)", "score": 26.9931545258, "published": true}], "hash": "1956550fb135a0c71c9db570b03d5479", "id": 3}, {"size": 2, "snippet_links": [{"key": "natural-person", "type": "clause", "offset": [25, 39]}, {"key": "citizen-of-the-united-states", "type": "definition", "offset": [53, 81]}], "snippet": "Persons. Subscriber is a natural person who is (i) a citizen of the United States or (ii) a resident of the United States, even if not a citizen. \u200b", "samples": [{"hash": "9fHvcwOwxbL", "uri": "/contracts/9fHvcwOwxbL#for-us", "label": "Subscription Agreement (Stone Point Credit Corp)", "score": 36.225189209, "published": true}, {"hash": "bCQJsrV3xY1", "uri": "/contracts/bCQJsrV3xY1#for-us", "label": "Subscription Agreement (Stone Point Credit Corp)", "score": 35.2203979492, "published": true}], "hash": "78aae6ac51a4459c2717acef3e92c3b3", "id": 4}, {"size": 1, "snippet_links": [{"key": "government-end-users", "type": "clause", "offset": [0, 20]}, {"key": "the-application", "type": "clause", "offset": [21, 36]}, {"key": "related-documentation", "type": "definition", "offset": [41, 62]}, {"key": "commercial-items", "type": "clause", "offset": [68, 84]}, {"key": "commercial-computer-software-documentation", "type": "definition", "offset": [184, 226]}, {"key": "in-accordance-with", "type": "definition", "offset": [315, 333]}, {"key": "granted-to", "type": "definition", "offset": [607, 617]}, {"key": "terms-andconditions", "type": "definition", "offset": [654, 673]}], "snippet": "Government End Users The Application and related documentation are \"Commercial Items\", as that termis defined under 48 C.F.R. \u00a72.101, consisting of \"Commercial Computer Software\" and \"Commercial Computer Software Documentation\", as such terms are used under 48 C.F.R. \u00a712.212 or 48 C.F.R. \u00a7227.7202, as applicable. In accordance with 48 C.F.R. \u00a712.212 or 48 C.F.R. \u00a7227.7202-1 through 227.7202-4, as applicable, the Commercial Computer Software and Commercial Computer Software Documentation are being licensed to U.S. Government end users (a) only as Commercial Items and (b) with only those rights as are granted to all other end users pursuant to the terms andconditions herein.", "samples": [{"hash": "i7O60TFqmDM", "uri": "/contracts/i7O60TFqmDM#for-us", "label": "End User License Agreement", "score": 25.9364891052, "published": true}], "hash": "5053477558947bc9fdd1556b76a72b65", "id": 5}, {"size": 1, "snippet_links": [{"key": "ordinary-income", "type": "clause", "offset": [57, 72]}, {"key": "subject-to", "type": "clause", "offset": [74, 84]}, {"key": "tax-rates", "type": "clause", "offset": [97, 106]}, {"key": "constructively-own", "type": "definition", "offset": [194, 212]}, {"key": "the-combination", "type": "clause", "offset": [249, 264]}, {"key": "capital-gain-or-loss", "type": "definition", "offset": [282, 302]}, {"key": "equal-to", "type": "definition", "offset": [303, 311]}, {"key": "tax-basis", "type": "definition", "offset": [386, 395]}], "snippet": "Dowlais Shareholders, dividends are generally taxable as ordinary income, subject to any reduced tax rates or deductions provided under the IRC. U.S. Dowlais Shareholders who do not actually or constructively own any AAM Shares immediately prior to the Combination will recognise a capital gain or loss equal to the difference between the amount of cash received and such U.S. holder\u2019s tax basis in the portion of its Dowlais Shares that is exchanged for such cash.", "samples": [{"hash": "992RjqldaQQ", "uri": "/contracts/992RjqldaQQ#for-us", "label": "Co Operation Agreement (American Axle & Manufacturing Holdings Inc)", "score": 34.0773429871, "published": true}], "hash": "6ce59967a3b41f606999a11bb0d633ae", "id": 6}, {"size": 1, "snippet_links": [{"key": "tax-purposes", "type": "definition", "offset": [32, 44]}, {"key": "the-loan-parties", "type": "definition", "offset": [46, 62]}, {"key": "the-loans", "type": "clause", "offset": [87, 96]}, {"key": "the-other-obligations", "type": "clause", "offset": [101, 122]}, {"key": "applicable-loan-parties", "type": "definition", "offset": [158, 181]}, {"key": "contingent-payment", "type": "clause", "offset": [215, 233]}, {"key": "debt-instruments", "type": "definition", "offset": [234, 250]}, {"key": "meaning-of", "type": "definition", "offset": [262, 272]}, {"key": "treasury-regulation", "type": "clause", "offset": [273, 292]}, {"key": "to-file", "type": "definition", "offset": [364, 371]}, {"key": "tax-returns-and-reports", "type": "clause", "offset": [376, 399]}, {"key": "the-foregoing", "type": "clause", "offset": [443, 456]}, {"key": "required-by", "type": "definition", "offset": [475, 486]}, {"key": "applicable-law", "type": "clause", "offset": [487, 501]}], "snippet": "federal, state and local income tax purposes, the Loan Parties intend, and agree, that the Loans and the other Obligations (i) constitute indebtedness of the applicable Loan Parties and (ii) shall not be treated as contingent payment debt instruments within the meaning of Treasury Regulation Section 1.1275-4 (or any successor regulation). The Loan Parties agree to file all tax returns and reports, and to take no position inconsistent with the foregoing, unless otherwise required by applicable Law.", "samples": [{"hash": "aglAehkEtmh", "uri": "/contracts/aglAehkEtmh#for-us", "label": "Credit Agreement (New Fortress Energy Inc.)", "score": 35.6926762491, "published": true}], "hash": "2645b372f93f732be3deeebdc9f66c43", "id": 7}, {"size": 1, "snippet_links": [{"key": "the-us", "type": "clause", "offset": [61, 68]}, {"key": "tax-purposes", "type": "definition", "offset": [102, 114]}, {"key": "administration-of", "type": "clause", "offset": [165, 182]}, {"key": "within-the-united-states", "type": "clause", "offset": [197, 221]}, {"key": "to-exercise", "type": "clause", "offset": [230, 241]}, {"key": "primary-supervision", "type": "definition", "offset": [242, 261]}, {"key": "united-states-persons", "type": "definition", "offset": [292, 313]}, {"key": "residents-of-the", "type": "clause", "offset": [348, 364]}, {"key": "to-control", "type": "definition", "offset": [390, 400]}, {"key": "subject-to", "type": "clause", "offset": [470, 480]}], "snippet": "Persons. Subscriber is (i) an entity created or organized in the U.S. that is treated for U.S. income tax purposes as a partnership or corporation, (ii) a trust the administration of which a court within the United States is able to exercise primary supervision over or for which one or more United States persons (including individual citizens or residents of the U.S.) have the authority to control all substantial decisions, or (iii) an estate the income of which is subject to tax in the United States.", "samples": [{"hash": "hb9dDhqmDps", "uri": "/contracts/hb9dDhqmDps#for-us", "label": "Transfer Agreement (Muzinich & Co., Inc.)", "score": 31.2286109924, "published": true}], "hash": "b44b2410cbb90af74cc929d853287128", "id": 8}, {"size": 1, "snippet_links": [{"key": "government-end-users", "type": "clause", "offset": [0, 20]}, {"key": "agrees-to", "type": "clause", "offset": [32, 41]}, {"key": "comply-with", "type": "definition", "offset": [42, 53]}, {"key": "equal-opportunity-laws", "type": "definition", "offset": [69, 91]}, {"key": "the-provisions-of", "type": "clause", "offset": [119, 136]}, {"key": "executive-order-11246", "type": "clause", "offset": [137, 158]}, {"key": "as-amended", "type": "definition", "offset": [160, 170]}, {"key": "section-402", "type": "clause", "offset": [172, 183]}, {"key": "section-503-of-the-rehabilitation-act-of-1973", "type": "clause", "offset": [267, 312]}, {"key": "the-regulations", "type": "clause", "offset": [330, 345]}, {"key": "affirmative-action", "type": "definition", "offset": [409, 427]}, {"key": "and-regulations", "type": "clause", "offset": [435, 450]}, {"key": "contained-in", "type": "definition", "offset": [451, 463]}, {"key": "incorporated-by-reference", "type": "definition", "offset": [496, 521]}, {"key": "in-this-agreement", "type": "definition", "offset": [522, 539]}], "snippet": "Government End Users, Stromasys agrees to comply with all applicable equal opportunity laws including, if appropriate, the provisions of Executive Order 11246, as amended, Section 402 of the Vietnam Era Veterans Readjustment Assistance Act of 1974 (38 USC 4212), and Section 503 of the Rehabilitation Act of 1973, as amended, and the regulations at 41 C.F.R. Parts 60 1 through 60 60, 60 250, and 60 741. The affirmative action clause and regulations contained in the preceding sentence shall be incorporated by reference in this Agreement.", "samples": [{"hash": "gdDz4yiycFz", "uri": "/contracts/gdDz4yiycFz#for-us", "label": "End User License Agreement", "score": 30.6136341095, "published": true}], "hash": "95095391e072816c54a4add88a1da8ea", "id": 9}, {"size": 1, "snippet_links": [{"key": "government-entities", "type": "clause", "offset": [24, 43]}, {"key": "a-us", "type": "clause", "offset": [59, 64]}, {"key": "state-government-entity", "type": "definition", "offset": [82, 105]}, {"key": "this-agreement", "type": "clause", "offset": [107, 121]}, {"key": "governing-law", "type": "definition", "offset": [144, 157]}], "snippet": "City, County, and State Government Entities. If Partner is a U.S. city, county or state government entity, this Agreement shall not specify any governing law or venue.", "samples": [{"hash": "gD8mtZBdBGB", "uri": "/contracts/gD8mtZBdBGB#for-us", "label": "Pulsepoint Aed Platform License Agreement", "score": 26.5824775696, "published": true}], "hash": "544861861347b3ef1d0bfd38a6917b77", "id": 10}], "next_curs": "Ck8SSWoVc35sYXdpbnNpZGVyY29udHJhY3RzcisLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ig9mb3ItdXMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"children": [], "size": 30, "title": "For U.S", "parents": [["for-erisa-stockholders-and-other-plan-investors", "For ERISA Stockholders and Other Plan Investors"], ["taxes", "Taxes"], ["inquiries", "Inquiries"], ["compliance-with-laws-disclosure", "Compliance with Laws; Disclosure"], ["term-and-termination", "Term and Termination"]], "id": "for-us", "related": [["introduction-to-your-subscriber-agreement", "INTRODUCTION TO YOUR SUBSCRIBER AGREEMENT", "INTRODUCTION TO YOUR SUBSCRIBER AGREEMENT"], ["data-mining", "Data Mining", "Data Mining"], ["cloud-services", "Cloud Services", "Cloud Services"], ["rdds", "RDDS", "RDDS"], ["subscription-services", "Subscription Services", "Subscription Services"]], "related_snippets": [], "updated": "2026-09-13T06:27:36+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The 'For U.S' clause designates that certain terms, conditions, or provisions within a contract are specifically applicable to parties, transactions, or activities within the United States. This clause typically clarifies that particular legal requirements, regulatory standards, or operational procedures are tailored to U.S. law or jurisdiction, and may differ from those in other countries. Its core function is to ensure compliance with U.S. legal frameworks and to avoid confusion by distinguishing obligations or rights that are unique to the U.S. context."}, "json": true, "cursor": ""}}